ESPE Abstracts (2015) 84 P-3-758

ESPE2015 Poster Category 3 Diabetes (94 abstracts)

A Case of Tacrolimus Related Posttranslated Diabetes Mellitus (PTDM)

Mehmet Keskin , Murat Karaoglan , Mehtap Akbalik Kara , Mithat Buyukcelik & Ozlem Keskin


Gaziantep University, Gaziantep, Turkey


Background: Tacrolimus is highly potent immunosuppressant agent. Despite it is quite prophylactic effect on renal allogreft rejection, the most marked side effect of tacrolimus is lead to posttranslated diabetes mellitus. There are some predictive risk factors which are determined on development of tacrolimus related diabetes mellitus: Advanced age, familial history, genetic factors, ethnicity, impaired glucose tolerance or metabolic syndrome in pre-transplantation period, obesity or overweight, immunosuppressant dose, additional other immunosuppressants,presence of associated hepatitis.

Objective: We present a case of tacrolimus related diabetes mellitus to pay attention predictive risk factors before renal transplantation.

Case: 15 years old boy had choronic renal failure due to vesicouretheral reflux. He was referred by Deparment of Pediatric Nephrology because of blood glucose level higher than normal. His weight was 42 kg and his height was 144 cm and his BMI was 22. Blood tension was arterial: 130/90 mm/Hg. When his health records of pre-transplantation period were revised, we realised that he had metabolic syndrome: Blood glusose test were as high as 280 mg/dl. LDL: 167 mg/dl. Triglyceride was 190 g/dl. He had hypertension. HbA1C was 4.1. when he was admitted to our clinic, his laboratory test were following: Glucose: 501 mg/dl, LDL: 182 mg/dl, triglyceride was 164 g/d,. HbA1C: 14.3,insulin: 2,2 U/mlC-peptide: 1.4. Islet cell antibodies (Anti-GAD, Anti-ICA, Anti-IA) were negative. After translanptation, he was given tacrolimus 0.15 mg/kg/day and prednisolone 0.5 mg/kg/day plus mycophenolate mofetil 1200 mg/m2/day. In the 12th weeks, he was diagnosed tacrolimus related diabetes mellitus. The our case had metabolic syndrome that is mentioned one of predictive risk factors.

Conclusion: We suggest to screen and be monitored predictive risk factors in pre-transplantaiton period. Measures should be taken to prevent modifiable risk factors.

Article tools

My recent searches

No recent searches.